Answers are grounded in this paper and cite their sources.
Hyperinflammation, hypercoagulation, and endothelial injury are major findings in acute and post-Covid-19. The SARS-CoV-2 S protein has been detected as an isolated element in human tissues reservoirs and is the main product of mRNA Covid-19 vaccines. In this review, we analyzed whether the S protein alone triggers pro-inflammatory and pro-coagulant responses in primary cultures of two human cell types deeply affected by SARS-CoV-2, such are monocytes and endothelial cells. Indeed, viral S protein activated NF-κB, promoted pro-inflammatory cytokines release, and triggered the priming and activation of the NLRP3 inflammasome system resulting in mature IL-1β formation. This was paralleled by enhanced production of coagulation factors such as von Willebrand factor (vWF), factor VIII, or tissue factor. Additionally, S protein failed to enhance ADAMTS-13 levels to counteract the pro-coagulant activity of vWF multimers. Our data also indicate that these effects of the S protein are mediated by toll like-receptors-4 in monocytes, but not in endothelial cells. On the other hand, it is known that premature vascular aging and endothelial cell senescence are major risk factors for cardiovascular diseases and atherothrombotic disturbances, which are main complications of both acute and long Covid-19. The S protein of SARS-CoV2 enhanced cell senescence and DNA damage response markers (senescence-associated-β galactosidase, γH2AX), as well as growth-arrest effectors (p53, p21, p16). In parallel, the S protein reduced the availability of cytoprotective proteins, such as the anti-aging protein klotho, Nrf2 or heme oxygenase-1. In conclusion, S protein behaves both as a pro-inflammatory and pro-coagulant stimulus in human monocytes and endothelial cells. Furthermore, treating the cells with recombinant klotho or angiotensin-(1-7) protected against the S protein induced pro-senescence, pro-inflammatory, and pro-oxidant actions. Globally, our data proposes novel mechanisms of disease for Covid-19 and its vascular sequelae and provides pharmacological clues to prevent such complications.
No takes yet. Share an insight, caveat, or question.
Sánchez‐Ferrer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: